Cells depend on the precise reading of DNA sequences to function correctly. This process, known as gene expression, determines which genetic instructions are activated. When this fails, the wrong parts of the genome can be activated, leading to cancers and neurodevelopmental disorders. Scientists at the University of Geneva (UNIGE) have identified two proteins that play a key role in regulating this essential mechanism, paving the way for promising new treatments that could be more effective and less toxic than those currently available. Their findings are published in Nature Communications.

The recently published study offers new insights into KRAS, a gene that’s known to be involved in almost half of all cancers. It could be a step toward developing “ultrapersonalized” treatments for colon cancer, with therapies that precisely target not just the specific genes involved in a patient’s cancer but individual mutations of that gene.

Adding the oncolytic virus immunotherapy pelareorep to paclitaxel chemotherapy warrants further investigation in patients with HR+ HER2- metastatic breast cancer whose disease has progressed after standard first-line treatment, according to PrECOG, LLC, the cancer research group that investigated the combination in the BRACELET-1 (PrECOG 0113) randomized phase 2 trial. 

Organ transplant recipients with advanced cancer, an often overlooked group in cancer care, may benefit from immunotherapy drugs, according to a new study.

The major international study, published in the prestigious JAMA Oncology journal, has revealed promising signs that cancer-fighting immunotherapy drugs, long considered too risky for organ transplant patients, may offer real benefits when carefully managed.

In this April 2025 issue of Annals of Thoracic Surgery (JCR Q1, IF: 3.6), a retrospective study, led by Professors Jianxing He and Shuben Li from the First Affiliated Hospital of Guangzhou Medical University, illustrated the safety, feasibility, and efficacy of extended sleeve lobectomy (ESL) after neoadjuvant immunochemotherapy in patients with centrally located non-small cell lung cancer (NSCLC).

The article entitled "Extended Sleeve Lobectomy After Neoadjuvant Immunochemotherapy for Centrally Located Non-small Cell Lung Cancer". It is the first study to evaluate the impact of neoadjuvant immunochemotherapy on ESL. The results demonstrated that ESL after neoadjuvant immunochemotherapy is a viable and safe option for selected patients with centrally located NSCLC to avoid pneumonectomy(PN), especially when standard sleeve lobectomy (SSL) is insufficient for R0 resection.